Sec Form 4 Filing - Wrighton-Smith Peter @ Oxford Immunotec Global PLC - 2017-07-05

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Wrighton-Smith Peter
2. Issuer Name and Ticker or Trading Symbol
Oxford Immunotec Global PLC [ OXFD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last) (First) (Middle)
C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE
3. Date of Earliest Transaction (MM/DD/YY)
07/05/2017
(Street)
ABINGDON, OXFORDSHIRE, X0OX14 4RZ
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 07/05/2017 M 16,438 A $ 0.81 ( 1 ) 478,106 D
Ordinary Shares 07/05/2017 S( 2 ) 16,438 D $ 16.5822 ( 3 ) 461,668 D
Ordinary Shares 07/05/2017 M 16,394 A $ 0.81 ( 1 ) 478,062 D
Ordinary Shares 07/05/2017 S( 2 ) 16,394 D $ 16.5822 ( 3 ) 461,668 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Follo wing Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 0.81 07/05/2017 M 16,438 ( 4 ) 02/17/2020 Ordinary Shares 16,438 $ 0 0 D
Stock Option (Right to Buy) $ 0.81 07/05/2017 M 16,394 ( 5 ) 12/31/2022 Ordinary Shares 16,394 $ 0 176,441 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Wrighton-Smith Peter
C/O OXFORD IMMUNOTEC GLOBAL PLC
94C INNOVATION DRIVE
ABINGDON, OXFORDSHIRE, X0OX14 4RZ
X Chief Executive Officer
Signatures
/s/ Elizabeth M. Keiley, as Attorney-in-Fact for Peter Wrighton-Smith 07/07/2017
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The original exercise price of these options was priced in GBP at GBP0.51 and converted to US$ at an exchange rate of US$1.58823=1GBP.
( 2 )The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
( 3 )The price reported for the sales on July 5, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.275 to $16.83 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
( 4 )Exercise from an option granted February 28, 2013, which became fully vested on April 1, 2014.
( 5 )Exercise from an option granted November 7, 2012, which became fully vested on December 31, 2016.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.